Wave Life Sciences Ltd. cash flow to debt ratio of -1.06K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Wave Life Sciences Ltd.'s free cash flow has decreased 23.38% from $-151.96M last year to $-187.49M, signaling decreasing performance

Wave Life Sciences Ltd.'s debt to equity ratio is 0.10, which means that the company's assets are healthy financed, signaling financial stability.

Wave Life Sciences Ltd.'s debt has decreased relative to shareholder equity from 0.12 last year to 0.10 today, signaling strengthened financials

Wave Life Sciences Ltd. has a net cash position, so leverage is healthy.

Wave Life Sciences Ltd. earns at least as much interest as it pays. Interest obligations are fully covered.

Wave Life Sciences Ltd.'s profit margin has decreased (245.79%) in the last year from -89.57% to -309.73%, signaling decreasing performance

Wave Life Sciences Ltd.'s short-term assets of $614.81M exceed its short-term liabilities of $95.06M

Wave Life Sciences Ltd.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Wave Life Sciences Ltd.'s return on equity of -50.12%, is lower than 15.00%, indicating bad performance

Wave Life Sciences Ltd.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Wave Life Sciences Ltd. had positive net income in only 0 out of 5 years, indicating unstable earnings

Wave Life Sciences Ltd. has negative free cash flow, indicating the company is burning cash rather than generating it

Wave Life Sciences Ltd. has negative free cash flow, indicating cash burn

Wave Life Sciences Ltd.'s yearly earnings has decreased 110.68% since last year from $-97.01M to $-204.38M, signaling decreasing performance

Wave Life Sciences Ltd.'s yearly revenue has decreased 60.55% since last year from $108.30M to $42.73M, signaling decreasing performance

ROIC -42.64% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Wave Life Sciences Ltd.'s 3-year revenue CAGR of 127.08% is positive, indicating growing revenue over the past 3 years

Wave Life Sciences Ltd. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Wave Life Sciences Ltd. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Wave Life Sciences Ltd. has insufficient data to evaluate this check.

Wave Life Sciences Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Wave Life Sciences Ltd. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Wave Life Sciences Ltd. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Wave Life Sciences Ltd. is overvalued relative to its fair value price of -15.20 based on Earnings Fair Value model

Wave Life Sciences Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Wave Life Sciences Ltd. has a price-to-book ratio of 2.70x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Wave Life Sciences Ltd. has a price-to-sales ratio of 18.76x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue